Coherus Oncology (CHRS) Total Debt Growth (5y) (2019 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Coherus Oncology | 216.87 Mn | 49.83 Mn | 8.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.04% |
| Dec 31, 2025 | -13.03% |
| Sep 30, 2025 | 6.87% |
| Jun 30, 2025 | -13.02% |
| Mar 31, 2025 | 19.10% |
| Dec 31, 2024 | -7.34% |
| Sep 30, 2024 | 11.94% |
| Jun 30, 2024 | 11.99% |
| Mar 31, 2024 | 22.87% |
| Sep 30, 2023 | 57.68% |
| Jun 30, 2023 | 57.26% |
| Mar 31, 2023 | 57.35% |
| Dec 31, 2022 | 56.78% |
| Sep 30, 2022 | 55.69% |
| Jun 30, 2022 | 49.18% |
| Mar 31, 2022 | 48.66% |
| Dec 31, 2021 | 21.43% |
| Sep 30, 2021 | 20.21% |
| Jun 30, 2021 | 19.09% |
| Mar 31, 2021 | 19.16% |
| Dec 31, 2020 | 64.83% |
| Sep 30, 2020 | 31.75% |
| Dec 31, 2019 | 89.72% |
| Sep 30, 2019 | 50.03% |